Immunic Inc (NASDAQ:IMUX) vice president of investor relations and communications Jessica Breu speaks with Proactive’s Stephen Gunnion about the company’s recent progress in multiple sclerosis (MS) trials, as well as its participation at the BIO-Europe conference in Stockholm, Sweden.
Breu highlighted that the BIO-Europe event is one of the largest biopharma networking gatherings, where Immunic engaged with other industry leaders, investors, and media to advance its strategic goals.
During the interview, Breu discussed recent interim data from the company’s Phase 3 ENSURE program f or vidofludimus calcium in relapsing MS. She shared that an independent data monitoring committee found the trials to be on track, with no need for a sample size increase. “This was really a very nice outcome for us because the trials can continue as planned without any changes,” said Breu, emphasizing that these findings help confirm Immunic’s program progress.
Breu also mentioned upcoming milestones, including the Phase 2B CALLIPER …